JAK inhibitor S-Ruxolitinib, Purity ≥98%

Cat. No.: X23-10-ZQ415

JAK inhibitor S-Ruxolitinib, Purity ≥98%

Synonym: S-Ruxolitinib; 941685-37-6; S-Ruxolitinib (INCB018424); Ruxolitinib (S enantiomer); Ruxolitinib S enantiomer; (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; JAK inhibitor

  • CAS Number: 941685-37-6
  • Compound CID: 50878566
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
S-Ruxolitinib, soluble in DMSO, water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, TYK2, c-Met, Chk2, JAK2, and JAK3.
Molecular Weight
306.37
Molecular Formula
C17H18N6
Targets
JAK1: 3.3 nM; TYK2: 19 nM; c-Met: >10 μM; Chk2: >1 μM; JAK2: 2.8 nM; JAK3: 428 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 59 mg/mL (192.57 mM); Water: 5 mg/mL (16.32 mM); Ethanol: 59 mg/mL (192.57 mM)
Identity
Confirmed by NMR/HPLC/MS.
Stability
The product is stable for three years when stored at the recommended temperature in lyophilized powder.
Applications
S-Ruxolitinib can be utilized to investigate the stereospecific inhibition of JAK1 and JAK2.
Storage
Store at -20ºC.
Related Products

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.